Brazil · Delayed Price · Currency is BRL AstraZeneca Statistics
Total Valuation
AstraZeneca has a market cap or net worth of BRL 1.66 trillion. The enterprise value is 1.79 trillion.
| Market Cap | 1.66T |
| Enterprise Value | 1.79T |
Important Dates
The last earnings date was Tuesday, February 10, 2026.
| Earnings Date | Feb 10, 2026 |
| Ex-Dividend Date | Feb 19, 2026 |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -0.06% |
| Shares Change (QoQ) | +0.13% |
| Owned by Insiders (%) | 0.03% |
| Owned by Institutions (%) | 65.46% |
| Float | 1.54B |
Valuation Ratios
The trailing PE ratio is 29.56 and the forward PE ratio is 20.30.
| PE Ratio | 29.56 |
| Forward PE | 20.30 |
| PS Ratio | 5.15 |
| PB Ratio | 6.20 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 25.69 |
| P/OCF Ratio | 20.74 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 17.71, with an EV/FCF ratio of 27.59.
| EV / Earnings | 31.75 |
| EV / Sales | 5.93 |
| EV / EBITDA | 17.71 |
| EV / EBIT | 24.39 |
| EV / FCF | 27.59 |
Financial Position
The company has a current ratio of 0.94, with a Debt / Equity ratio of 0.61.
| Current Ratio | 0.94 |
| Quick Ratio | 0.65 |
| Debt / Equity | 0.61 |
| Debt / EBITDA | 1.51 |
| Debt / FCF | 2.52 |
| Interest Coverage | 10.47 |
Financial Efficiency
Return on equity (ROE) is 22.84% and return on invested capital (ROIC) is 15.85%.
| Return on Equity (ROE) | 22.84% |
| Return on Assets (ROA) | 8.19% |
| Return on Invested Capital (ROIC) | 15.85% |
| Return on Capital Employed (ROCE) | 17.12% |
| Weighted Average Cost of Capital (WACC) | 5.17% |
| Revenue Per Employee | 3.37M |
| Profits Per Employee | 586,049 |
| Employee Count | 96,100 |
| Asset Turnover | 0.54 |
| Inventory Turnover | 1.81 |
Taxes
In the past 12 months, AstraZeneca has paid 11.95 billion in taxes.
| Income Tax | 11.95B |
| Effective Tax Rate | 17.49% |
Stock Price Statistics
The stock price has increased by +22.55% in the last 52 weeks. The beta is 0.19, so AstraZeneca's price volatility has been lower than the market average.
| Beta (5Y) | 0.19 |
| 52-Week Price Change | +22.55% |
| 50-Day Moving Average | 168.89 |
| 200-Day Moving Average | 148.76 |
| Relative Strength Index (RSI) | 58.80 |
| Average Volume (20 Days) | 581 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, AstraZeneca had revenue of BRL 323.53 billion and earned 56.32 billion in profits. Earnings per share was 36.02.
| Revenue | 323.53B |
| Gross Profit | 264.35B |
| Operating Income | 78.72B |
| Pretax Income | 68.31B |
| Net Income | 56.32B |
| EBITDA | 106.19B |
| EBIT | 78.72B |
| Earnings Per Share (EPS) | 36.02 |
Balance Sheet
The company has 31.50 billion in cash and 163.60 billion in debt, with a net cash position of -132.10 billion.
| Cash & Cash Equivalents | 31.50B |
| Total Debt | 163.60B |
| Net Cash | -132.10B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 268.34B |
| Book Value Per Share | 172.84 |
| Working Capital | -10.43B |
Cash Flow
In the last 12 months, operating cash flow was 80.28 billion and capital expenditures -15.48 billion, giving a free cash flow of 64.80 billion.
| Operating Cash Flow | 80.28B |
| Capital Expenditures | -15.48B |
| Free Cash Flow | 64.80B |
| FCF Per Share | n/a |
Margins
Gross margin is 81.71%, with operating and profit margins of 24.33% and 17.41%.
| Gross Margin | 81.71% |
| Operating Margin | 24.33% |
| Pretax Margin | 21.11% |
| Profit Margin | 17.41% |
| EBITDA Margin | 32.82% |
| EBIT Margin | 24.33% |
| FCF Margin | 20.03% |
Dividends & Yields
This stock pays an annual dividend of 2.70, which amounts to a dividend yield of 1.51%.
| Dividend Per Share | 2.70 |
| Dividend Yield | 1.51% |
| Dividend Growth (YoY) | -2.79% |
| Years of Dividend Growth | 4 |
| Payout Ratio | 47.39% |
| Buyback Yield | 0.06% |
| Shareholder Yield | 1.58% |
| Earnings Yield | 3.38% |
| FCF Yield | 3.89% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on February 2, 2026. It was a reverse split with a ratio of 0.5.
| Last Split Date | Feb 2, 2026 |
| Split Type | Reverse |
| Split Ratio | 0.5 |
Scores
AstraZeneca has an Altman Z-Score of 3.24 and a Piotroski F-Score of 6.
| Altman Z-Score | 3.24 |
| Piotroski F-Score | 6 |